Petra Muus - Concepedia

Author

Petra Muus

Also Known As

Elena Palmisani, Helmut R. Salih, M. Blunden, MUUS, P, Muus, Petra, P Muus, P. MUUS, P. Muus, Petra M. Wandernoth (149629), Petra Muus

299

Publications

12K

Citations

H-Index

120

Concepts

All Affiliations

Radboud University Nijmegen Radboud University Medical Center European Organisation for Research and Treatment of Cancer Sapienza University of Rome Leiden University Medical Center

About

Petra Muus is an author at Radboud University Nijmegen specializing in medicine, hematology, and oncology.

Top Concepts

#	Concept	H-Index	Publications	Citations
1	Medicine	21	40	1.8K
2	Health Sciences	13	16	867
3	Natural Sciences	2	2	79
4	Business	1	1	22
5	Language Studies	1	1	22

Petra Muus

106

Publications

11.2K

Citations

H-Index

Page 1

	Year	Citations
Terminal Complement Inhibitor Eculizumab in Atypical Hemolytic–Uremic Syndrome Christophe Legendre, Christoph Licht, Petra Muus, New England Journal of Medicine	2013	1.5K
The Complement Inhibitor Eculizumab in Paroxysmal Nocturnal Hemoglobinuria Peter Hillmen, Neal S. Young, Jörg Schubert, New England Journal of Medicine	2006	1.2K
Effect of the complement inhibitor eculizumab on thromboembolism in patients with paroxysmal nocturnal hemoglobinuria Peter Hillmen, Petra Muus, Ulrich Dührsen, Blood	2007	572
Low-Dose Decitabine Versus Best Supportive Care in Elderly Patients With Intermediate- or High-Risk Myelodysplastic Syndrome (MDS) Ineligible for Intensive Chemotherapy: Final Results of the Randomized Phase III Study of the European Organisation for Research and Treatment of Cancer Leukemia Group and the German MDS Study Group Michael Lübbert, Stefan Suciu, Liliana Baila, Journal of Clinical Oncology	2011	546
A randomized phase 3 study of lenalidomide versus placebo in RBC transfusion-dependent patients with Low-/Intermediate-1-risk myelodysplastic syndromes with del5q Pierre Fenaux, Aristoteles Giagounidis, Dominik Selleslag, Blood	2011	475
Molecular remission in PML/RAR alpha-positive acute promyelocytic leukemia by combined all-trans retinoic acid and idarubicin (AIDA) therapy. Gruppo Italiano-Malattie Ematologiche Maligne dell'Adulto and Associazione Italiana di Ematologia ed Oncologia Pediatrica Cooperative Groups. Franco Mandelli, Daniela Diverio, Giuseppe Avvisati, PubMed	1997	474
Efficacy and safety of eculizumab in atypical hemolytic uremic syndrome from 2-year extensions of phase 2 studies Christoph Licht, Larry A. Greenbaum, Petra Muus, Kidney International	2015	406
Long‐term safety and efficacy of sustained eculizumab treatment in patients with paroxysmal nocturnal haemoglobinuria Peter Hillmen, Petra Muus, Alexander Röth, British Journal of Haematology ImmunohematologyRenal PathologyRenal InflammationDialysis TherapyGlomerulonephritis	2013	377
Gemtuzumab Ozogamicin Versus Best Supportive Care in Older Patients With Newly Diagnosed Acute Myeloid Leukemia Unsuitable for Intensive Chemotherapy: Results of the Randomized Phase III EORTC-GIMEMA AML-19 Trial Sergio Amadori, Stefan Suciu, Dominik Selleslag, Journal of Clinical Oncology	2016	341
Eltrombopag Added to Immunosuppression in Severe Aplastic Anemia Régis Peffault de Latour, Austin Kulasekararaj, Simona Iacobelli, New England Journal of Medicine	2022	265

Page 1